AI-generated analysis, not investment advice. The articles are written by AI, edited, and checked against company filings — but the judgements are opinions and the figures go stale. How this is made · Terms

✦ The Future BetsNarrow moat

Gilead Sciences (GILD) — the future bets

Gilead's HIV bets extend a franchise it already leads; its oncology bets cost $11.3 billion in one half-year and must beat a poor acquisition record.

Gilead's future bets fall into two groups: extending HIV past Biktarvy, and buying a second franchise. The first is cheaper and more likely to work. The second is where most of the money goes.

Gilead acquired IPR&D expense ($bn)5.120195.920200.920210.920221.220234.720241.0202511.3H1 2026Gilead Forms 10-K FY2020, FY2025; SEC XBRL; Q2 2026 results release
Half a year of 2026 cost more than any full year before it.

The HIV bets are built on lenacapavir, patented to 20371. The weekly treatment pill with Merck had positive Phase 3 results in 2026, and oral lenacapavir for weekly PrEP has an FDA decision date of 2 February 20272. These extend a franchise Gilead already leads.

The oncology bets are expensive. Gilead spent $11.3 billion on acquired IPR&D in the first half of 20263: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro4. It also has Trodelvy's new first-line breast cancer approval5 and an anito-cel decision date of 23 December 20266. In liver disease, Livdelzi and Hepcludex are growing7.

The company describes "over 50 clinical-stage programs"8. Breadth is not the issue; conversion is. Gilead's past oncology purchases have produced large impairments, and its cell therapy sales are shrinking.

There is also a smaller, earlier bet in cell therapy. In the fourth quarter of 2025 Gilead announced the acquisition of Interius BioTherapeutics for about $350 million9, a company developing in vivo chimeric antigen receptor therapies, which engineer cells inside the body rather than outside it. It is small next to Arcellx, but it shows where Kite's next generation is meant to come from if the current, manufactured-per-patient model keeps losing ground.

The bets are rated narrow with a widening trajectory, because the HIV extensions are progressing and the oncology launches are close. If none of anito-cel, Trodelvy and the weekly HIV pill adds $1 billion of annual sales by 2029, the future will look a great deal like the present: one franchise, and a large bill for trying to find another.

Moat trajectory: Widening

Three HIV and oncology decisions due between December 2026 and February 2027.

The number that tests this moat
Reported
Acquired IPR&D, latest half-year
$11,290M (H1 2026), from $315M a year earlier

The cost of the bets; repeated at this scale without new product revenue would mean Gilead is buying hope, not franchises.

Source: Gilead Sciences Q2 2026 results release ↗
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
Arcellx and the Myeloma Bet
Gilead paid an implied $7.8 billion for Arcellx's anito-cel, a late entry into a myeloma market where Carvykti is growing 49% a year.
✦ FUTURE BET 02
Once a Week: Islatravir, Lenacapavir and Oral PrEP
Gilead's weekly pills, for treatment with Merck and for prevention on its own, carry lenacapavir patents to 2037 and are the bridge past Biktarvy.
✦ FUTURE BET 03
Liver Disease Grows Again: Livdelzi and Hepcludex
Gilead's liver business grew 10% in Q2 2026 on Livdelzi and Hepcludex, chronic-disease drugs bought with CymaBay and MYR.
✦ FUTURE BET 04
Trodelvy in First-Line Breast Cancer
Trodelvy won first-line breast cancer in 2026 as its lung-cancer hopes were written off; Immunomedics's IPR&D impairments now total about $8.65…
References
  1. ReportedThe HIV bets are built on lenacapavir, patented to 2037.
    Gilead Sciences Form 10-K for 2025 - Item 1A risk factors and pricing regulation: the IRA, Medicare negotiation, Medicaid, the ACA and tariffs. — FY2025 · publ. 24 February 2026 · source ↗
  2. ReportedThe weekly treatment pill with Merck had positive Phase 3 results in 2026, and oral lenacapavir for weekly PrEP has an FDA decision date of 2 February 2027.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  3. ReportedGilead spent $11.3 billion on acquired IPR&D in the first half of 2026: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  4. ReportedGilead spent $11.3 billion on acquired IPR&D in the first half of 2026: $7.0 billion for Arcellx, $3.1 billion for Tubulis and $1.0 billion for Ouro.
    Gilead Sciences Form 10-Q for the quarter ended 30 June 2026 - acquired IPR&D for Arcellx, Tubulis and Ouro, the $1.75 billion Trodelvy impairment, debt, receivables and the December 2025 agreement with the US administration. — Q2 2026 · publ. 6 August 2026 · source ↗
  5. ReportedIt also has Trodelvy's new first-line breast cancer approval and an anito-cel decision date of 23 December 2026.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  6. ReportedIt also has Trodelvy's new first-line breast cancer approval and an anito-cel decision date of 23 December 2026.
    Gilead Sciences release of 23 February 2026, Form 8-K exhibit 99.1 - agreement to acquire Arcellx for $115 a share plus a $5 contingent value right, an implied equity value of $7.8 billion; anito-cel PDUFA date 23 December 2026. — February 2026 · publ. 23 February 2026 · source ↗
  7. ReportedIn liver disease, Livdelzi and Hepcludex are growing.
    Gilead Sciences second-quarter 2026 results release, Form 8-K exhibit 99.1 - revenue by product, income statement, cash flow, balance sheet, pipeline updates and 2026 guidance - pipeline, regulatory and business development updates. — Q2 2026 · publ. 4 August 2026 · source ↗
  8. ReportedThe company describes "over 50 clinical-stage programs".
    Gilead Sciences Form 10-K for 2025 - Item 1 business and the revenue-by-product table: products, programs, employees and manufacturing. — FY2025 · publ. 24 February 2026 · source ↗
  9. ReportedIn the fourth quarter of 2025 Gilead announced the acquisition of Interius BioTherapeutics for about $350 million, a company developing in vivo chimeric antigen receptor therapies, which engineer cells inside the body rather than outside it.
    Gilead Sciences Form 10-K for 2025 - Item 1 business and the revenue-by-product table: products, programs, employees and manufacturing. — FY2025 · publ. 24 February 2026 · source ↗
Sources
Generated October 4, 2026